Sarepta Therapeutics, Inc. SRPT Operating Lease Right-of-Use Assets in Other Assets
Operating Lease Right-of-Use Assets in Other Assets at other companies
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sarepta Therapeutics, Inc.'s operating lease right-of-use assets in other assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sarepta Therapeutics, Inc.'s operating lease right-of-use assets in other assets?
- Sarepta Therapeutics, Inc. (SRPT) reported operating lease right-of-use assets in other assets of $124.06M in Q1 2026.
- How has Sarepta Therapeutics, Inc.'s operating lease right-of-use assets in other assets changed year-over-year?
- Sarepta Therapeutics, Inc.'s operating lease right-of-use assets in other assets decreased by 15.6% year-over-year, from $147.06M to $124.06M.
- What is the long-term trend for Sarepta Therapeutics, Inc.'s operating lease right-of-use assets in other assets?
- Over 5 years (2020 to 2025), Sarepta Therapeutics, Inc.'s operating lease right-of-use assets in other assets has grown at a 6.5% compound annual growth rate (CAGR), from $91.76M to $125.5M.